Story perspectives

Rep. Moolenaar Demands Chinese Trial Data, Pushes Biotech Security Act

7/1/2026

Summary

Story summary

Rep. John Moolenaar (R-Mich.) chaired a House China probe and sent letters to five drugmakers demanding Chinese trial data by July 17.
The letters request due-diligence, data-protection and consent details for Xinjiang and PLA hospitals, noting Merck’s claim of patient safety and limited comment from other firms.
Moolenaar backs the Biotech Investment National Security Act, adding biotech to outbound-investment review and aligning with President Donald Trump’s Biosecure Act.

1 of 1

Story summary

Rep. John Moolenaar (R-Mich.) chaired a House China probe and sent letters to five drugmakers demanding Chinese trial data by July 17.
The letters request due-diligence, data-protection and consent details for Xinjiang and PLA hospitals, noting Merck’s claim of patient safety and limited comment from other firms.
Moolenaar backs the Biotech Investment National Security Act, adding biotech to outbound-investment review and aligning with President Donald Trump’s Biosecure Act.